Report Detail
Global Neuroendocrine Tumors (NETs) Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- RnM3536837 |
- 18 June, 2019 |
- Global |
- 119 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
Neuro Emotional Technique (NET) is a psycho-emotional therapy based on the physiological foundations of stress-related responses. As discovered in the late 1970’s, emotional responses are composed of neuropeptides (amino acid chains) and their receptors, which lie on neurons and other cells of remote tissues in the body. The neuropeptides are ejected from the neuron and carry the encoded “information” to other sites within the body. These neuropeptides are in a category of neurochemicals known as Information Substances (IS). ISs are released at times of stress-related arousal and become attached to remotely-positioned neuroreceptors.
Scope of the Report:
The worldwide market for Neuroendocrine Tumors (NETs) Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Neuroendocrine Tumors (NETs) Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Advanced Accelerator Applications
AVEO Oncology
Boehringer Ingelheim International
Hutchison MediPharma Limited
IpsenPharma
Novartis AG
Pfizer, Inc
Progenics Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Somatostatin Analogs (SSAs)
Targeted Therapy
Other
Market Segment by Applications, can be divided into
Hospitals
Clinics
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroendocrine Tumors (NETs) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroendocrine Tumors (NETs) Treatment, with price, sales, revenue and global market share of Neuroendocrine Tumors (NETs) Treatment in 2017 and 2018.
Chapter 3, the Neuroendocrine Tumors (NETs) Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroendocrine Tumors (NETs) Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Neuroendocrine Tumors (NETs) Treatment market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Neuroendocrine Tumors (NETs) Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
- 1.1 Neuroendocrine Tumors (NETs) Treatment Introduction
- 1.2 Market Analysis by Type
- 1.2.1 Somatostatin Analogs (SSAs)
- 1.2.2 Targeted Therapy
- 1.2.3 Other
- 1.3 Market Analysis by Applications
- 1.3.1 Hospitals
- 1.3.2 Clinics
- 1.3.3 Other
- 1.4 Market Analysis by Regions
- 1.4.1 North America (United States, Canada and Mexico)
- 1.4.1.1 United States Market States and Outlook (2014-2024)
- 1.4.1.2 Canada Market States and Outlook (2014-2024)
- 1.4.1.3 Mexico Market States and Outlook (2014-2024)
- 1.4.2 Europe (Germany, France, UK, Russia and Italy)
- 1.4.2.1 Germany Market States and Outlook (2014-2024)
- 1.4.2.2 France Market States and Outlook (2014-2024)
- 1.4.2.3 UK Market States and Outlook (2014-2024)
- 1.4.2.4 Russia Market States and Outlook (2014-2024)
- 1.4.2.5 Italy Market States and Outlook (2014-2024)
- 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- 1.4.3.1 China Market States and Outlook (2014-2024)
- 1.4.3.2 Japan Market States and Outlook (2014-2024)
- 1.4.3.3 Korea Market States and Outlook (2014-2024)
- 1.4.3.4 India Market States and Outlook (2014-2024)
- 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
- 1.4.4 South America, Middle East and Africa
- 1.4.4.1 Brazil Market States and Outlook (2014-2024)
- 1.4.4.2 Egypt Market States and Outlook (2014-2024)
- 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
- 1.4.4.4 South Africa Market States and Outlook (2014-2024)
- 1.4.4.5 Turkey Market States and Outlook (2014-2024)
- 1.4.1 North America (United States, Canada and Mexico)
- 1.5 Market Dynamics
- 1.5.1 Market Opportunities
- 1.5.2 Market Risk
- 1.5.3 Market Driving Force
2 Manufacturers Profiles
- 2.1 Advanced Accelerator Applications
- 2.1.1 Business Overview
- 2.1.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.2 AVEO Oncology
- 2.2.1 Business Overview
- 2.2.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.2.2.1 Product A
- 2.2.2.2 Product B
- 2.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.3 Boehringer Ingelheim International
- 2.3.1 Business Overview
- 2.3.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.3.2.1 Product A
- 2.3.2.2 Product B
- 2.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.4 Hutchison MediPharma Limited
- 2.4.1 Business Overview
- 2.4.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.4.2.1 Product A
- 2.4.2.2 Product B
- 2.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.5 IpsenPharma
- 2.5.1 Business Overview
- 2.5.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.5.2.1 Product A
- 2.5.2.2 Product B
- 2.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.6 Novartis AG
- 2.6.1 Business Overview
- 2.6.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.6.2.1 Product A
- 2.6.2.2 Product B
- 2.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.7 Pfizer, Inc
- 2.7.1 Business Overview
- 2.7.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.7.2.1 Product A
- 2.7.2.2 Product B
- 2.7.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.8 Progenics Pharmaceuticals
- 2.8.1 Business Overview
- 2.8.2 Neuroendocrine Tumors (NETs) Treatment Type and Applications
- 2.8.2.1 Product A
- 2.8.2.2 Product B
- 2.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
- 3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Manufacturer (2017-2018)
- 3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Manufacturer (2017-2018)
- 3.3 Market Concentration Rate
- 3.3.1 Top 3 Neuroendocrine Tumors (NETs) Treatment Manufacturer Market Share in 2018
- 3.3.2 Top 6 Neuroendocrine Tumors (NETs) Treatment Manufacturer Market Share in 2018
- 3.4 Market Competition Trend
4 Global Neuroendocrine Tumors (NETs) Treatment Market Analysis by Regions
- 4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Regions
- 4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Regions (2014-2019)
- 4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Regions (2014-2019)
- 4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 4.3 Europe Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 4.4 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 4.5 South America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 4.6 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
5 North America Neuroendocrine Tumors (NETs) Treatment by Country
- 5.1 North America Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
- 5.1.1 North America Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2014-2019)
- 5.1.2 North America Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2014-2019)
- 5.2 United States Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 5.3 Canada Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 5.4 Mexico Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
6 Europe Neuroendocrine Tumors (NETs) Treatment by Country
- 6.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
- 6.1.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2014-2019)
- 6.1.2 Europe Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2014-2019)
- 6.2 Germany Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 6.3 UK Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 6.4 France Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 6.5 Russia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 6.6 Italy Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
7 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment by Country
- 7.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
- 7.1.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2014-2019)
- 7.1.2 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2014-2019)
- 7.2 China Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 7.3 Japan Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 7.4 Korea Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 7.5 India Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 7.6 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
8 South America Neuroendocrine Tumors (NETs) Treatment by Country
- 8.1 South America Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
- 8.1.1 South America Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2014-2019)
- 8.1.2 South America Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2014-2019)
- 8.2 Brazil Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 8.3 Argentina Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 8.4 Colombia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
9 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment by Countries
- 9.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Country
- 9.1.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Country (2014-2019)
- 9.1.2 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Country (2014-2019)
- 9.2 Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 9.3 Turkey Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 9.4 Egypt Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 9.5 Nigeria Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
- 9.6 South Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2014-2019)
10 Global Neuroendocrine Tumors (NETs) Treatment Market Segment by Type
- 10.1 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Market Share by Type (2014-2019)
- 10.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales and Market Share by Type (2014-2019)
- 10.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Type (2014-2019)
- 10.2 Somatostatin Analogs (SSAs) Sales Growth and Price
- 10.2.1 Global Somatostatin Analogs (SSAs) Sales Growth (2014-2019)
- 10.2.2 Global Somatostatin Analogs (SSAs) Price (2014-2019)
- 10.3 Targeted Therapy Sales Growth and Price
- 10.3.1 Global Targeted Therapy Sales Growth (2014-2019)
- 10.3.2 Global Targeted Therapy Price (2014-2019)
- 10.4 Other Sales Growth and Price
- 10.4.1 Global Other Sales Growth (2014-2019)
- 10.4.2 Global Other Price (2014-2019)
11 Global Neuroendocrine Tumors (NETs) Treatment Market Segment by Application
- 11.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2014-2019)
- 11.2 Hospitals Sales Growth (2014-2019)
- 11.3 Clinics Sales Growth (2014-2019)
- 11.4 Other Sales Growth (2014-2019)
12 Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.1 Global Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Growth Rate (2019-2024)
- 12.2 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Regions (2019-2024)
- 12.2.1 North America Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.2.2 Europe Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.2.3 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.2.4 South America Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.2.5 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Forecast (2019-2024)
- 12.3 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Type (2019-2024)
- 12.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2019-2024)
- 12.3.2 Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Type (2019-2024)
- 12.4 Neuroendocrine Tumors (NETs) Treatment Market Forecast by Application (2019-2024)
- 12.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2019-2024)
- 12.4.2 Global Neuroendocrine Tumors (NETs) Treatment Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
- 13.1 Sales Channel
- 13.1.1 Direct Marketing
- 13.1.2 Indirect Marketing
- 13.1.3 Marketing Channel Future Trend
- 13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
- 15.1 Methodology
Summary:
Get latest Market Research Reports on Neuroendocrine Tumors (NETs) Treatment . Industry analysis & Market Report on Neuroendocrine Tumors (NETs) Treatment is a syndicated market report, published as Global Neuroendocrine Tumors (NETs) Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Neuroendocrine Tumors (NETs) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
